Company: BIVIW
Filing Date: 2025-07-03
Form Type: S-1
Source: 0001520138-25-000198
Chunk: 17

Company: BIOVIE INC.
Filing Date: 2025-07-03
Form: S-1
Chunk 17
---
 | We intend to use the net proceeds from this offering for working capital                                                                                                                                                                                                                                                                                                                                                                                                                                
 and general corporate purposes. See “Use of Proceeds” for a more complete description of the intended use of proceeds from                                                                                                                                                                                                                                                                                                                                                                              
 this offering.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Risk factors:    |     | Investing in our securities involves a high degree of risk. See “Risk                                                                                                                                                                                                                                                                                                                                                                                                                                   
 Factors” beginning on page 9 and the similarly titled sections in the documents incorporated by reference into this prospectus for                                                                                                                                                                                                                                                                                                                                                                      
 a discussion of the factors you should consider carefully before you decide to invest in our securities.                                                                                                                                                                                                                                                                                                                                                                                                |
| Listing:         |     | Our Common Stock is listed on Nasdaq under the symbol “BIVI.”  There is no established trading market for the Pre-funded Warrants or Warrants. We intend to apply to list the Warrants on Nasdaq under the symbol “BIVIW”. We cannot guarantee that the Warrants will be approved for listing on Nasdaq. We do not intend to list the Pre-funded Warrants on any securities exchange or nationally recognized trading system and do not expect a trading market to develop for the Pre-funded Warrants. |

The number of shares of our Common Stock outstanding before this offering and to be outstanding after this offering is based on 1,860,086 shares of our Common Stock outstanding as of June 30, 2025, and excludes:

| · | 84,872 shares of our Common Stock issuable upon the exercise of outstanding 
 stock options at a weighted average exercise price of $ 286.20 per share;   |

| · | 960,098 shares of our Common Stock issuable upon the exercise of outstanding 
 warrants at a weighted average exercise price of $35.02 per share;           |

| · | 7,212 shares of our Common Stock issuable upon vesting of restricted 
 stock units issued under our equity incentive plan.                  |

Unless otherwise indicated, this prospectus supplement reflects and assumes the following:

| · | no exercise of outstanding options or warrants; |

| · | no exercise of the underwriters’ over-allotment option; |

| · | no exercise of the Pre-Funded Warrants and Warrants issued and sold in this offering; and |

| · | no exercise of the Representative’s Warrants to be issued upon consummation of this offering at an 
 exercise price equal to 125% of the offering price of our Common Stock.                            |

<div align